Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$151.66 USD

151.66
839,853

-1.83 (-1.19%)

Updated Nov 5, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

BMY vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BMY vs. ILMN: Which Stock Is the Better Value Option?

GILD vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to Illumina Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products.

Debanjana Dey headshot

Coronavirus Diagnostic Tests in High Demand: 4 Stocks in Focus

by Debanjana Dey

Amid the pandemic, these four companies with strong diagnostics testing developments might show better resilience.

The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, NextEra Energy, Goldman Sachs and Illumina

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, NextEra Energy, Goldman Sachs and Illumina

Illumina Takes Over BlueBee, Fortifies NGS Data Processing

by Zacks Equity Research

With this acquisition, the cloud capability of BlueBee's platform will help Illumina (ILMN) to lower the cost of storing, sharing and managing the company's huge volumes of genomic data.

Sheraz Mian headshot

Top Research Reports for Netflix, Bristol-Myers & NextEra

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Bristol-Myers Squibb (BMY) and NextEra Energy (NEE).

GILD vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Boston Scientific's Single-Use Duodenoscope Gets TPT Class Nod

by Zacks Equity Research

Boston Scientific's (BSX) EXALT Model D Single-Use Duodenoscope, approved for a TPT payment class by the CMS, will aid Medicare beneficiaries to enjoy the benefits of new and innovative devices.

Illumina's (ILMN) NGS Test for Detecting Coronavirus Gets EUA

by Zacks Equity Research

Illumina's (ILMN) NGS-based test for the detection of the SARS-CoV-2 receives the FDA's EUA to enable high-volume screening.

Myriad Genetics' Test Better Predicts Drug Levels Per Study

by Zacks Equity Research

Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.

Medtronic's StealthStation Feature Recall Classified Class I

by Zacks Equity Research

This is not the first time, Medtronic's (MDT) StealthStation surgical navigation system is facing product recall.

Globus Medical Faces Business Loss Amid Coronavirus Crisis

by Zacks Equity Research

Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.

Edwards Lifesciences' SAPIEN 3 THV Cleared for Use in China

by Zacks Equity Research

Edwards Lifesciences' (EW) SAPIEN 3 THV to be used an alternative to open-heart surgery for high and extreme-risk AS patients post approval in China.

Medtronic Resolute Onyx Gets CE Mark for 1-Month DAPT Therapy

by Zacks Equity Research

Medtronic's (MDT) gets CE Mark recognition for a shorter DAPT indication for HBR patients with Resolute Onyx DES implantation who are at higher risk of bleeding.

IDEXX OPTI Medical Gets CE Mark for RT-PCR Coronavirus Test

by Zacks Equity Research

This test by IDEXX (IDXX) benefits from an optimized workflow and claims to deliver greater assurance of quality and accuracy.

Bio-Rad Rides on New Coronavirus Tests Amid Cost Concerns

by Zacks Equity Research

The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues results from robust demand for coronavirus testing and related research.

Here's Why You Should Hold on to Haemonetics Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.

Haemonetics (HAE) Inks Deal With GVS for Blood Filter Supply

by Zacks Equity Research

Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.

Abbott Stock Down on Urgent Field Safety Notice for TactiCath

by Zacks Equity Research

Abbott (ABT) also mentions certain guidelines related to product return, reporting, and customer assistance.

LabCorp's New Website Offers Patients Coronavirus Trial Details

by Zacks Equity Research

LabCorp's (LH) Covance business benefits from collaborations with leading pharmaceutical and biotechnology companies.

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Teleflex (TFX) on robust segmental and geographical growth.

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on robust segmental growth and regulatory approvals.

Sreoshi Bera headshot

Digital Transformation Stocks to Stay Hot in 2020: 5 Picks

by Sreoshi Bera

The coronavirus pandemic has forced businesses to make digital transformations. As automation holds the key, these five stocks are poised to rally further.

Bruker Rides on PCI Sales, Coronavirus-Led Supply Issues Hurt

by Zacks Equity Research

Bruker (BRKR) expects a rise in sales within life science, biopharma and basic medical research, as well as in infectious disease diagnostics due to the pandemic.